Ozempic is about to become generic for billions of people
Ozempic will soon be available as a generic drug in many populous countries, significantly lowering its price and improving accessibility.
A. Grzegorzewska, Gedeon Richter: Asian business enters the European drug market
Aneta Grzegorzewska discusses the aggressive strategy of Indian pharmaceutical companies entering the European market with generic products.
A. Grzegorzewska, Gedeon Richter: Asian Business Enters the European Drug Market
The article discusses the aggressive strategy of Indian companies seeking to enter the European generic drug market as Europe aims for greater autonomy in pharmaceuticals.
Cheaper copies of Ozempic will soon flood the market. India's patent expires on Friday
India is set to see the expiration of a patent for the diabetes drug Ozempic, paving the way for cheaper alternatives to enter the market.
The H-hour for obesity drugs is Friday
The patent for the obesity treatment drug semaglutide will expire in India on Friday, leading to potential price reductions and increased market competition.
Ozempic: With the expiration of the patent will prices fall? Will we have a generic version? See what to expect now
The patent on semaglutide, the active ingredient in Ozempic, expires in Brazil, possibly leading to lower prices and generic versions of the drug in the future.
South Africa: Bringing It Home - South Africa is Leading the Charge to Make Anti-HIV jab for Africa
South Africa's National Aids Council is soliciting local drug companies to apply for the creation of generic versions of the anti-HIV jab lenacapavir, targeting a goal to end AIDS in the country by 2043.
EMS agrees to buy Medley, a brand of generic drugs from Sanofi
The EMS Group has agreed to acquire 100% of Medley, a leading generic drug brand in Brazil, from the French pharmaceutical company Sanofi.
The generic drug market is changing the dynamics
Significant changes in the generic drug market are set to transform its dynamics by 2026, with major mergers and acquisitions already altering the sector.
Pharmaceutical company Dr. Reddy's prepares to launch a cheap generic Ozempic in India in March
Indian pharmaceutical company Dr. Reddy’s Laboratories is set to launch a generic version of the diabetes drug Ozempic, named Obeda, in March 2026 following the expiration of the semaglutide patent.
The patent for the most expensive diabetes drug has been revoked. Are cheaper alternatives closer to reimbursement?
A patent for dapagliflozin, a leading diabetes medication, has been revoked, potentially paving the way for cheaper generic versions to be reimbursed in Poland.
The Dangers of Drug Price Cuts Based on Fiscal Logic
The South Korean government's policy to reduce drug prices raises concerns about its potential negative impact on public health and the domestic pharmaceutical industry's sustainability.
Are Generic Drugs Cut to Create New Drugs? … It’s a Misdiagnosis
The ongoing debate surrounding the Ministry of Health and Welfare's proposal to lower the prices of generic drugs in South Korea has raised concerns about its implications for new drug development and the pharmaceutical industry.
A generic Ozempic for 15 euros per month or how to revolutionize the obesity drug market
The expiration of Novo Nordisk's patent in some countries pressures the Danish pharmaceutical company as its diabetes injection Ozempic becomes synonymous with weight loss globally.